Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.
Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.
复制标题
接受放化疗的胰腺癌患者自我报告症状的模式。
DOI：
10.1016/j.jpainsymman.2006.11.007
复制
发表时间：
2007
影响因子：
4.7
通讯作者：
Crane,Christopher
中科院分区：
文献类型：
--
作者：
Reyes-Gibby,CielitoC;Chan,Wenyaw;Abbruzzese,JamesL;Xiong,HenryQ;Ho,Linus;Evans,DouglasB;Varadhachary,Gauri;Bhat,Samrat;Wolff,RobertA;Crane,Christopher
Pancreatic cancer is a lethal disease characterized by multiple disease-related symptoms. Chemoradiation therapy is a standard of treatment for locally advanced pancreatic cancer. Although shown to prolong survival, there is little information about treatment-related symptoms or the palliative benefits of chemoradiation. We assessed symptoms of patients with locally advanced pancreatic cancer receiving chemoradiation to determine the prevalence, and co-occurrence, of symptoms and to identify the extent to which symptoms interfered with function. Forty-eight patients were treated with chemoradiation on a Phase I protocol. Patients received radiotherapy (50.4Gy in 28 fractions), capecitabine (median dose 825mg/m2twice daily), and bevacizumab (2.5–10mg/kg). Symptom severity and its interference with function were prospectively assessed (at presentation, during, and after chemoradiation) in 43 consenting patients using the M.D. Anderson Symptom Inventory. Results showed that 95% of patients reported at least one of the 13 symptoms assessed at presentation. The most commonly reported symptoms of moderate to severe (≥5 on a 0–10 scale) intensity at presentation were lack of appetite (24%), pain (19%), fatigue (19%), and sleep disturbance (10%). We observed an increase in patients reporting moderate to severe fatigue, nausea, and sleep disturbance during chemoradiation. McNemar tests for paired binary observations showed the proportion of patients reporting moderate to severe symptoms significantly (P<0.001) decreased after chemoradiation at 94 days follow-up (lack of appetite=7%, pain=7%, fatigue=13%, sleep disturbance=7%). This study demonstrates the feasibility and usefulness of symptom assessment in chemoradiation protocols. Future studies with larger cohorts are needed to further characterize multiple symptoms associated with chemoradiation.
